Organigram’s stock soars as British American Tobacco invests $91.3 million

“The opportunity set within the cannabis space has grown significantly,” Organigram said. “The category continues to expand globally as more adult consumers incorporate cannabis into their lives. The competitive nature of the industry also means that the opportunity for investments is ample for companies with strong balance sheets, industry experience and a proven track record of M&A success.”

Organigram
OGI,
+27.67%

OGI,
+29.31%
plans to use C$83.1 million of the investment from British American Tobacco Plc
BATS,
-0.77%
to create “Jupiter,” an investment pool for emerging growth opportunities aimed at growing Organigram’s geographic footprint.

The remaining C$41.5 million be used for general corporate purposes.

Organigram’s stock rose by 36 cents to $1.52 a share, but provided little lift to other Canadian cannabis companies, which traded mixed.

Tilray Brands Inc.
TLRY,
-2.01%
dipped by 0.8%, Canopy Growth Corp.
CGC,
-2.66%
rose by 0.2%, TerrAscend Corp.
TSNDF,
-2.18%
fell by 0.9%, SUNDL Inc. (SunDial Growers)
SNDL,
-1.49%
rose 0.3% and Aurora Cannabis Inc.
ACB,
+1.22%
advanced by 3.7%.

The investment will raise British American Tobacco’s stake in Organigram to 45% including non-voting preferred shares, up from 20%. The companies started collaborating in 2021.

Jefferies analyst Owen Bennett reiterated a buy rating on Organigram and said the deal comes after British American Tobacco made an investment in German cannabis company, Sanity, in 2022.

Bennett said the two companies could be taking aim at the much larger U.S. market.

“While OGI right now can’t get exposure to [the U.S.] market due to current legal status, this may now change in the next 12-24 months,” Bennett said. “We believe the U.S. — from a cannabis value creation perspective — really is the holy grail, so we find it interesting BAT has provided this additional investment at this time.”

Organigram said the investment from British American Tobacco furthers its support of the company “as a trusted partner and accelerates the focus on innovative cannabis science and R&D outside of combustibles.”

A product-development collaboration is now in late-stage development of emulsions, vapor formulations, new flavors and packaging to be applied to Organigram products in 2024.

Organigram’s stock has fallen 64% in the year to date, while the AXS Cannabis ETF
THCX,
+1.04%
has fallen 36% and the S&P 500
SPX,
+0.12%
has gained 13.5%.

Along with British American Tobacco, other big corporations have already waded into the cannabis space.

Altria
MO,
-0.07%
owns a stake in Cronos Group
CRON,
-0.27%

CRON,
+0.39%,
and Constellation Brands Inc.
STZ,
+0.46%
has invested billions in Canopy Growth Corp.
CGC,
-2.66%.

Imperial Bands
IMBBY,
-0.31%
  has invested in Canada’s Auxly Cannabis Group
CBWTF,
0.66.